User menu

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.

Bibliographic reference Van Den Neste, Eric ; Cazin, Bruno ; Janssens, Ann ; González-Barca, Eva ; Terol, María José ; et. al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.. In: Cancer Chemotherapy and Pharmacology, Vol. 71, no. 3, p. 581-591 (2013)
Permanent URL
  1. Dighiero G, Hamblin TJ, Chronic lymphocytic leukaemia, 10.1016/s0140-6736(08)60456-0
  2. Pleyer Lisa, Egle Alexander, Hartmann Tanja Nicole, Greil Richard, Molecular and cellular mechanisms of CLL: novel therapeutic approaches, 10.1038/nrclinonc.2009.72
  3. Butler Tom, Gribben J.G., Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia, 10.1016/j.blre.2010.03.004
  4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, 10.1016/s0140-6736(10)61381-5
  5. Badoux X. C., Keating M. J., Wang X., O'Brien S. M., Ferrajoli A., Faderl S., Burger J., Koller C., Lerner S., Kantarjian H., Wierda W. G., Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL, 10.1182/blood-2010-08-304683
  6. Robak Tadeusz, Dmoszynska Anna, Solal-Céligny Philippe, Warzocha Krzysztof, Loscertales Javier, Catalano John, Afanasiev Boris V., Larratt Loree, Geisler Christian H., Montillo Marco, Zyuzgin Ilya, Ganly Peter S., Dartigeas Caroline, Rosta András, Maurer Jörg, Mendila Myriam, Saville M. Wayne, Valente Nancy, Wenger Michael K., Moiseev Sergey I., Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia, 10.1200/jco.2009.26.4556
  7. Hamblin A. D., Hamblin T. J., The immunodeficiency of chronic lymphocytic leukaemia, 10.1093/bmb/ldn034
  8. Gribben John G, Chronic lymphocytic leukemia: planning for an aging population, 10.1586/era.10.127
  9. Zenz Thorsten, Eichhorst Barbara, Busch Raymonde, Denzel Tina, Häbe Sonja, Winkler Dirk, Bühler Andreas, Edelmann Jennifer, Bergmann Manuela, Hopfinger Georg, Hensel Manfred, Hallek Michael, Döhner Hartmut, Stilgenbauer Stephan, TP53Mutation and Survival in Chronic Lymphocytic Leukemia, 10.1200/jco.2009.27.8762
  10. Döhner Hartmut, Stilgenbauer Stephan, Benner Axel, Leupolt Elke, Kröber Alexander, Bullinger Lars, Döhner Konstanze, Bentz Martin, Lichter Peter, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, 10.1056/nejm200012283432602
  11. Van Den Neste Eric, Van den Berghe Georges, Bontemps Françoise, AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies, 10.1517/13543781003703694
  12. Dixon Ross, Fujitaki James, Sandoval Tamie, Kisicki James, Acadesine (AICA-Riboside): Disposition and Metabolism of an Adenosine-Regulating Agent, 10.1002/j.1552-4604.1993.tb01929.x
  13. Drew Brian G, Kingwell Bronwyn A, Acadesine, an adenosine-regulating agent with the potential for widespread indications, 10.1517/14656566.9.12.2137
  14. Campas C., Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes, 10.1182/blood-2002-07-2339
  15. Santidrian A. F., Gonzalez-Girones D. M., Iglesias-Serret D., Coll-Mulet L., Cosialls A. M., de Frias M., Campas C., Gonzalez-Barca E., Alonso E., Labi V., Viollet B., Benito A., Pons G., Villunger A., Gil J., AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells, 10.1182/blood-2010-05-283960
  16. Sturm I, Bosanquet A G, Hermann S, Güner D, Dörken B, Daniel P T, Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy, 10.1038/sj.cdd.4401194
  17. Pairet S, Ferrer A, Abella E, Vela M, Longarón R, Campàs C, de Frias M, Espinet B, Besses C, Serrano S, Bellosillo B (EHA meeting abstracts) (2010) Acadesine-induced citotoxicity in chronic lymphocytic leukemia is independent of immunoglobulin mutational status and Zap70 expression. Haematologica 95(suppl 2):313, abstract no. 0753
  18. Hallek M., Cheson B. D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M. J., Montserrat E., Rai K. R., Kipps T. J., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, 10.1182/blood-2007-06-093906
  19. Menasché Philippe, Jamieson W.R. Eric, Flameng Willem, Michael K. Davies, Acadesine: A new drug that may improve myocardial protection in coronary artery bypass grafting, 10.1016/s0022-5223(05)80179-5
  20. Mangano Dennis T., Miao Yinghui, Tudor Iulia C., Dietzel Cynthia, Post-Reperfusion Myocardial Infarction, 10.1016/j.jacc.2006.04.044
  21. Montraveta A, de Frias M, Campàs C, Campo E, Roue G, Colomer D (ASH Annual Meeting Abstracts), (2010) The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma Blood 116:3918-Abstract 3918
  22. Baumann Philipp, Mandl-Weber Sonja, Emmerich Bertold, Straka Christian, Schmidmaier Ralf, Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells, 10.1016/j.yexcr.2007.06.020